Syntekabio Expands into Screening, Precision Medicine, and Animal Vaccines to Secure New Revenue Sources

AI drug development company Syntekabio is expanding its business areas beyond its existing artificial intelligence (AI) and genome analysis operations to encompass screening and diagnostics, precision medicine, pharmaceuticals and medical devices, and veterinary pharmaceuticals and vaccines. The company’s strategy is to move beyond a research and development-centered structure by utilizing its existing technology and infrastructure to add revenue-generating business lines, thereby diversifying its profit model.

Syntekabio announced that it will convene an extraordinary general meeting of shareholders on September 15 to propose amendments to its articles of incorporation aimed at broadening its business scope. The company explained that the expansion of business purposes is intended to secure new growth engines and facilitate diversification for the pursuit of new business initiatives.

The new business areas being added include a bio-screening and diagnostic platform, genome analysis and precision medicine, as well as in vitro, molecular, and genome diagnostics. The company will also add the manufacturing, distribution, and sales of prescription and non-prescription medicines, medical devices, and in vitro diagnostic medical devices to its business purposes.

The business expansion will also reach into the animal healthcare sector. This includes veterinary pharmaceuticals and vaccines, livestock disease control, and research and development related to veterinary medicine, as well as the addition of animal health supplements and pet healthcare products to the list of business purposes.

Furthermore, the company will include health functional foods and functional materials and products, anti-aging testing and management systems, AI-based healthcare, digital health, and bio-convergence projects.

Rather than treating the new businesses as independent ventures separate from its core AI drug development operations, Syntekabio is focusing on commercializing them by leveraging its existing technology and infrastructure. The company plans to extend the technologies accumulated through AI drug development and genome analysis into screening and diagnostics, precision medicine, digital health, and related products and services.

In particular, Syntekabio aims to establish a business link from genome analysis through screening, diagnostics, and precision medicine to digital health, and to diversify its revenue sources by expanding its product portfolio to include pharmaceuticals, medical devices, veterinary pharmaceuticals, and vaccines.

The company will prioritize and sequentially commercialize business areas with a high potential for revenue generation. In the core AI drug development activity, it intends to boost achievements such as technology licensing and joint development, while in new business lines, it will seek to secure product and service revenue, thereby supplementing its research and development-heavy business structure.

Through this approach, Syntekabio aims to create a virtuous cycle involving the strengthening of its core business, the expansion of related businesses, and the generation of new revenue sources, with the goal of increasing sales and improving operating profit and loss simultaneously.

The company is also accelerating its business normalization efforts. Syntekabio plans to organize the necessary documentation and procedures to promptly pursue a new audit, aiming to secure an ‘unqualified’ audit opinion. Subsequently, in accordance with the relevant requirements and procedures, the company intends to shed its status as an “investment warning stock” and restore the confidence of the market and its shareholders.

A Syntekabio representative stated, “This expansion of business objectives is not about changing the direction of our existing operations, but about broadening the scope of our accumulated AI and genome technologies and infrastructure in order to secure new growth engines and revenue sources. We will focus on materializing these plans initially in high-potential sectors, to achieve tangible sales growth and improvements in operating profit and loss.”

The representative added, “We will also expedite procedures designed to normalize management, secure an unqualified audit opinion through a prompt re-audit, and move swiftly to exit the investment warning category, doing our utmost to restore market confidence.”

This content was produced with the assistance of AI translation services.